CLENBUTEROLFREEBASE
CLENBUTEROL
CAS: 37148-27-9
Molecular Formula: C12H18Cl2N2O
CLENBUTEROLFREEBASE - Names and Identifiers
CLENBUTEROLFREEBASE - Physico-chemical Properties
| Molecular Formula | C12H18Cl2N2O |
| Molar Mass | 277.19 |
| Density | 1.42 g/cm3 |
| Boling Point | 404.9±40.0 °C(Predicted) |
| pKa | 13.29±0.20(Predicted) |
| Storage Condition | 0-6°C |
| Physical and Chemical Properties | Chemical Properties The hydrochloride (C12H18CI2N2O · HCI) of this product is white or almost white crystalline powder. Melting point 174 -175.5 ℃. Soluble in water, methanol, ethanol, slightly soluble in chloroform, acetone, insoluble in ether, odorless, slightly bitter taste. |
| Use | Use antiasthmatic medicine. This product is an epinephrine bronchial antispasmodic drug. It has good selectivity for the excitatory effect of bronchial smooth muscle β2 receptor, and the intensity of bronchial dilatation is 100 times that of Shuchuanning. Used to treat bronchial asthma, asthmatic bronchitis, etc. The therapeutic dose of the product is 0.5 μg/kg, and the oral LD50 for animals (mice, rats, rabbits) is about 300,000 times the dose. |
CLENBUTEROLFREEBASE - Risk and Safety
| UN IDs | 3249 |
| HS Code | 29221990 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
CLENBUTEROLFREEBASE - Upstream Downstream Industry
CLENBUTEROLFREEBASE - Uses and synthesis methods
overview
Clenbuterol ((RS)-1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol) is a β2-adrenoceptor agonist. When entering the blood, clenbuterol stimulates adrenoceptors in the muscle, increasing the metabolism of carbohydrates and fats, and the metabolism and synthesis of proteins in the striated muscle. In addition to its known (and therapeutic) effects on the smooth muscles of the bronchial tree and blood vessels, clenbuterol can also increase the mass and strength of muscles.
Pharmacological Study
Gao Jingpeng et al. discussed the effect of clenbuterol on diaphragm cell apoptosis and expression of apoptosis-related protein Fas in chronic obstructive pulmonary disease (COPD) model rats. Methods: Male SPF grade W istar rats were randomly divided into three groups: A, B and C. Each group was further divided into subgroups of 4 weeks before modeling, 2 weeks after modeling and 4 weeks after modeling. Group A was fed normally. Group B and C were modeled by tracheal injection of lipopolysaccharide (LPS) and smoking. Group C was given clenbuterol intervention on the basis of modeling. The apoptosis rate and Fas expression rate of diaphragmatic cells in each group were detected by phosphodeoxyuracil nick end labeling and immunohistochemistry. Results: After 4 weeks, the model of group B and C was successfully established by HE section of lung. With the passage of time, there was no statistical difference in the positive rate of apoptosis and Fas expression among subgroups in group a. the two-week and four-week subgroups in group B and group c were significantly higher than those in group a at the same time (p <0.01), and there was no statistical difference between subgroups in group B and group c. The positive rate of apoptosis in subgroups of group c at 2 weeks and 4 weeks was significantly lower than that in group B at the same time (P<0.05). Conclusion: Smoke and LPS participate in the regulation of diaphragm cell apoptosis during the formation of COPD. Clenbuterol may reduce diaphragm cell apoptosis by inhibiting oxidative stress and down-regulating Fas expression, and has certain therapeutic effect on diaphragm fatigue caused by COPD.
Clenbuterol
Clenbuterol, also known as clenbuterol, is a β-adrenergic agonist (β-stimulant for short), which is commonly used in medicine to treat asthma. It has the effect of promoting animal growth, reducing fat content, and increasing lean meat percentage, so it is often used as a feed additive, commonly known as clenbuterol. It will form residues in animal tissues. People can cause poisoning after eating pork containing clenbuterol, usually with muscle tremor, heart palpitations, mental tension, nausea, dizziness and other symptoms. Our government banned clenbuterol hydrochloride as a feed additive in 1997.
Production method
It is obtained by reduction, chlorination, bromination of p-nitroacetophenone, condensation with tert-butylamine, and reduction with potassium borohydride. The hydrochloride of this product is after salt is formed.
category
Toxic substances
Toxicity classification
Highly toxic
Acute toxicity
intravenous-mouse LD50: 27.6 mg/kg
flammability hazard characteristics
Combustible, decomposes toxic chlorides and nitrogen oxide gases during combustion
storage and transportation features
The warehouse is low temperature, ventilated and dry; stored separately from food ingredients
Fire extinguishing agent
Water, carbon dioxide, dry powder, sand
Last Update：2024-04-10 22:29:15
Supplier List
Multiple SpecificationsSpot supply
Product Name: Clenbuterol Visit Supplier Webpage Request for quotationCAS: 37148-27-9
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: CLENBUTEROL Visit Supplier Webpage Request for quotationCAS: 37148-27-9
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Multiple SpecificationsSpot supply
Product Name: Clenbuterol Visit Supplier Webpage Request for quotationCAS: 37148-27-9
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: CLENBUTEROL Visit Supplier Webpage Request for quotationCAS: 37148-27-9
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
View History
Raw Materials for CLENBUTEROLFREEBASE